Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 1/2008

01-07-2008 | Letter to the Editor

All-trans-retinoic acid as a possible cause of acute pancreatitis even in the absence of hypertriglyceridemia

Authors: Takumi Hoshino, Nahoko Hatsumi, Satoru Takada, Tohru Sakura, Shuichi Miyawaki

Published in: International Journal of Hematology | Issue 1/2008

Login to get access

Excerpt

The standard therapy for patients affected by acute promyelocytic leukemia (APL) is the administration of all-trans-retinoic acid (ATRA). ATRA therapy is usually well-tolerated, but it also has the potential to induce toxicity. The most severe side effect of ATRA is retinoic acid syndrome; the next is acute pancreatitis, which is a rare but serious adverse event mostly due to hypertriglyceridemia. We herein report a patient who developed ATRA-induced acute pancreatitis without hypertriglyceridemia. …
Literature
1.
Abou CL, Ghosn M, Ghayad E, Honein K. A case of pancreatitis associated with all-trans-retinoic acid therapy in acute promyelocytic leukemia. Haematol J. 2001;2:406–7.CrossRef
2.
3.
Yutsudo Y, Imoto S, Ozuru R, et al. Acute pancreatitis after all-trans retinoic acid therapy. Ann Hematol. 1997;74:295–6.CrossRefPubMed
4.
Teng HW, Bai LY, Chao TC, Wang WS, Chen PM. Acute pancreatitis during all-trans-retinoic acid treatment for acute promyelocytic leukemia in a patient without overt hypertriglyceridemia. Jpn J Clin Oncol. 2005;35(2):94–6.CrossRefPubMed
5.
Hatake K, Uwai M, Ohtsuko T, et al. Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management. Int J Hematol. 1997;66:13–9.CrossRefPubMed
6.
Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg. 2002;9:401–10.CrossRefPubMed
7.
Hsu HC, Tsai WH, Chen PG, Hsu ML, Ho CK, Wang SY. In vitro effect of granulocyte-colony stimulating factor and all-trans retinoic acid on the expression of inflammatory cytokines and adhesion molecules in acute promyelocytic leukemic cells. Eur J Haematol. 1999;63:11–8.CrossRefPubMed
8.
McCarroll JA, Phillips PA, Santucci N, Pirola RC, Wilson JS, Apte MV. Vitamin A inhibits pancreatic stellate cell activation: implications for treatment of pancreatic fibrosis. Gut. 2006;55(1):79–89.CrossRefPubMedPubMedCentral
Metadata
Title
All-trans-retinoic acid as a possible cause of acute pancreatitis even in the absence of hypertriglyceridemia
Authors
Takumi Hoshino
Nahoko Hatsumi
Satoru Takada
Tohru Sakura
Shuichi Miyawaki
Publication date
01-07-2008
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2008
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-008-0116-1

Other articles of this Issue 1/2008

International Journal of Hematology 1/2008 Go to the issue

Letter to the Editor

Karyotypically independent clones with del(11q) and trisomy 10 in acute myeloid leukemia: trisomy 10 may appear as an additional change

Original Article

JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera

Original Article

Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation

Original Article

Periostin and bone marrow fibrosis

Original Article

A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan

Original Article

Phagocytosis of co-developing neutrophil progenitors by dendritic cells in a culture of human CD34+ cells with granulocyte colony-stimulating factor and tumor necrosis factor-α
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits